Iodide

Iodide

SCHEMBL3551537

I.O=C(O)c1cc(I)ccn1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.59
▸ ALDH1A1 P00352 3/20 0.59
▸ KDM5A P29375 3/20 0.59
▸ KDM3A Q9Y4C1 2/20 0.59
▸ ASPH Q12797 2/20 0.59
▸ KDM8 Q8N371 2/20 0.59
▸ KDM4C Q9H3R0 2/20 0.59
▸ KDM5B Q9UGL1 2/20 0.59
▸ KDM6B O15054 1/20 0.59
▸ TET3 O43151 1/20 0.59
▸ KDM4A O75164 1/20 0.59
▸ BBOX1 O75936 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ KDM5C P41229 1/20 0.59
▸ KDM4D Q6B0I6 1/20 0.59
▸ TET2 Q6N021 1/20 0.59
▸ ALKBH5 Q6P6C2 1/20 0.59
▸ KDM7A Q6ZMT4 1/20 0.59
▸ TET1 Q8NFU7 1/20 0.59
▸ EGLN2 Q96KS0 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL232233 0.98 KDM4E (0.61) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL30524416 0.98 KDM4E (0.61) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL5700151 0.79 ALDH1A1 (0.50) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL19918058 0.79 ADORA3 (0.45) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL7513922 0.78 KMO (0.71) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL30800092 0.78 KMO (0.71) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL5700578 0.77 KMT2A (0.59) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL14897947 0.76 KDM4D (0.50) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL5700562 0.75 ALDH1A1 (0.43) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL2490793 0.75 ALDH1A1 (0.50) KDM4EALDH1A1KDM3AKDM4CKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550786-B2 4-fluoropiperidine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-01-24 — — US disclosed
EP-2945630-A1 4-FLUOROPIPERIDINE OREXIN RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2015-11-25 — — EP disclosed
US-20150322074-A1 4-FLUOROPIPERIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-11-12 — — US disclosed
WO-2014113303-A1 4-FLUOROPIPERIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2014-07-24 — — WO disclosed
US-7834015-B2 treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-11-16 — — US disclosed
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-08-20 — — US disclosed
EP-2032140-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2009-03-11 — — EP disclosed
WO-2007138355-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-12-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322074-A1 4-FLUOROPIPERIDINE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY4R KDM4E 689/4885ALDH1A1 2621/4885KDM5A 739/4885
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) PARP1, PARP2, PARP11 KDM4E 3630/4885ALDH1A1 139/4885KDM5A 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback